Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for liver diseases. Its primary asset and area of research targets the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The company's lead product candidate, through its proprietary cyclophilin inhibitor technology, aims to address both inflammation and fibrosis, which are key factors in liver disease progression. Hepion Pharmaceuticals operates within the healthcare and pharmaceutical sectors, with a strong emphasis on groundbreaking research and clinical trials. Headquartered in Edison, New Jersey, the company epitomizes innovation in drug development, aiming to meet unmet medical needs in liver disorders. By advancing its pipeline of therapeutics, Hepion Pharmaceuticals plays a significant role in both the biopharmaceutical industry and the broader effort to combat chronic liver diseases.